academic-industry relationships on the process and outcomes of biomedical research, the effects of local health care market competition on the activities and attitudes of medical school faculty, and the impact of data-sharing and withholding on academic science. In addition, he is researching the role of organizational culture in promoting patient safety. Dr. Campbell has published numerous articles in professional journals and has delivered numerous presentations at local, national, and international conferences on health care policy, medical education, and science policy.

C. Thomas Caskey is president and chief executive officer of Cogene Biotech Ventures, Ltd. In addition, he was recently elected president of the newly formed Texas Academy of Science, Engineering and Medicine. Dr. Caskey also served as senior vice president, human genetics and vaccines discovery, at Merck Research Laboratories, West Point, Pennsylvania, and president of the Merck Genome Research Institute. He serves as an adjunct professor at Baylor College of Medicine, Houston, Texas. Dr. Caskey earned his medical doctorate from Duke University, Durham, North Carolina. He has received numerous academic and industry-related honors. He is a member of the National Academy of Sciences and the Institute of Medicine. He is past president of American Society of Human Genetics and the Human Genome Organization. He served as chair, Advisory Panel on Forensic Uses of DNA Tests, Office of Technology Assessment, U.S. Congress, 1989-1990. He was a member of the Committee on DNA Technology in Forensic Science, National Research Council, National Academy of Sciences, 1989-1991.

Robert Cook-Deegan is director of the Center for Genome Ethics, Law, and Policy at Duke’s Institute for Genome Sciences and Policy. He is also research professor in Public Policy Studies and the Department of Medicine. Until July 2002, he directed the Robert Wood Johnson Foundation Health Policy Fellowship program at the Institute of Medicine, National Academy of Sciences. He worked on mental health policy, tobacco control, cancer policy, biomedical research policy, and federal R&D budgeting for 11 years at the National Academies, following a stint at the National Center for Human Genome Research, National Institutes of Health, in its inaugural year. He previously worked at the Office of Technology Assessment, U.S. Congress, for six years, joining OTA as a Congressional Science and Engineering Fellow directly from a postdoctoral position in molecular biology at the University of Colorado. He graduated from the University of Colorado Medical School in 1979 and from Harvard College (chemistry) in 1975. He chairs the Royalty Fund Advisory Committee for the Alzheimer’s Association and the external advisory board of a four-site project on genetic testing for Alzheimer’s susceptibility. He is secretary and trustee of the Foundation for Genetic Medicine and former chair of Section X (Social Impacts of Science and Engineering) for the American Association for the Advancement

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement